Summary
High-dose methotrexate (MTX) therapy with subsequent leucovorin (LV) rescue (HDMTX-LV) in the treatment of osteosarcoma is based on the assumption that this tumor has a deficient uptake system for MTX and reduced folates. To simulate features of HDMTX-LV therapy protocols in vitro, sensitive and MTX-resistant human osteosarcoma cell lines and a lymphoblastoid cell line were exposed to MTX and/or LV at various dosages and time schedules and the effects on DNA metabolism and on cell growth were evaluated. The data show that in osteosarcoma cells and in lymphoblasts the cytotoxic effects of 10-6 M to 10-7 M MTX can be substantially reversed by LV if the antidote is applied within the first 12 h of MTX exposure. The results are not consistent with the assumption mentioned above and should be taken into consideration when designing new therapeutic regimens. An alternative hypothesis for the efficacy of HDMTX-LV is discussed. It is concluded that HDMTX-LV therapy may by effective in the treatment of osteosarcoma, even when subpopulations of the tumor cells exhibit different mechanisms of resistance to MTX, such as elevated levels of dihydrofolate reductase or a deficient transport system for MTX, if high doses of MTX are applied long enough to ensure lethal intracellular MTX levels and low-dose LV schedules instituted after a long delay are used.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bleyer WA (1978) The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 41: 36
Chabner BA, Young RC (1973) Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52: 1804
Diddens H, Niethammer D, Jackson RT (1983) Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 43: 5286
Fry DW, Anderson LA, Borst M, Goldman ID (1983) Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 43: 1087
Goldmann ID (1975) Membrane transport of methotrexate (NSC-740) and other folate compounds: relevance to rescue protocols. Cancer Chemother Rep 6: 63
Huang CC, Moore GE (1969) Chromosomes of 14 hematopoietic cell lines derived from peripheral blood of persons with and without chromosome anomalies. J Natl Cancer Inst 43: 1119
Jaffe N, Frei E, Traggis D, Bishop Y (1974) Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Eng J Med 291: 994
Niethammer D, Jackson RC (1975) Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells. Eur J Cancer 11: 845
Poser RG, Sirotnak FM (1983) Studies on the in vivo synthesis of methotrexate polyglutamates and their efflux properties in normal, proliferative, and neoplastic mouse tissues. Adv Exp Med Biol 163: 251
Rosen G, Huvos AG, Mosende C, Beattie EJ, Exelby PR, Capparos B, Marcove RC (1978) Chemotherapy and thoracotomy for metastatic osteogenic sarcoma. A model for adjuvant chemotherapy and the rationale for the timing of thoracic surgery. Cancer 41: 841
Sauer H, Schalhorn A, Wilmanns W (1979) The biochemistry of the citrovorum factor rescue effect in normal bone marrow cells after high-dose methotrexate. Eur J Cancer 15: 1203
Sauer A, Schalhorn A (1980) Rationale Grundlagen und Praxis des Citrovorumfaktor (Leucovorin)-Schutzes nach hochdosierter Methotrexat-Therapie. Onkologie 3: 64
Schalhorn A, Sauer H, Wilmanns W, Stupp-Poutot G (1983) Methotrexate and methotrexate polyglutamates in human sarcoma metastases after high-dose methotrexate therapy. Klin Wochenschr 61: 1089
Schornagel JH, McVie JG (1983) The clinical pharmacology of methotrexate. Cancer Treat Rev 10: 53
Vogler WR, Israili ZH, Soliman A-G, Moffitts S, Barlogie B (1981) Marrow cell kinetics in patients treated with methotrexate and citrovorum factor. Cancer 47: 215
Wilmanns W, Kehr D (1970) DNS-Synthese in Leukämiezellen unter der Einwirkung von Methotrexat, 5-Fluoruracil und Cytosinarabinosid in vitro. Pharmacol Clin 2: 161
Author information
Authors and Affiliations
Additional information
This work was supported by the Deutsche Forschungsgemeinschaft (SFB 120: Leukämieforschung und Immungenetik)
Rights and permissions
About this article
Cite this article
Diddens, H., Teufel, T. & Niethammer, D. High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines. Cancer Chemother. Pharmacol. 20, 128–132 (1987). https://doi.org/10.1007/BF00253966
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00253966